

ESMO PRECEPTORSHIP PROGRAMME

GASTRIC CANCER

Multidisciplinary management, standards of care, therapeutic targets
and future perspectives

Singapore
3-4 December 2025

CHAIRS

Florian Lordick, Germany
Wei Peng Yong, Singapore

SPEAKERS

Takuji Gotoda, Japan
Hanneke van Laarhoven, Netherlands
Jeffrey Lum, Singapore
Matthew C. H. Ng, Singapore

Radka Obermannová, Czech Republic
Sun Young Rha, Republic of Korea
Jimmy B. Y. So, Singapore
Maria Wobith, Singapore

LEARNING OBJECTIVES

- To learn the fundamental of epidemiology, aetiology, pathogenesis, molecular events, and ethnic patterns as contributing factors to heterogeneity in gastric cancer (GC)
- To understand the importance of pathology and molecular factors
- To learn about best clinical practice in the multidisciplinary management of gastric and gastro-esophageal junction (GEJ) and esophageal squamous cell cancers in the adjuvant and metastatic settings
- To learn about current best practice for endoscopic and surgical resection of localised gastric cancer
- To be able to compare the benefits of neo-adjuvant, adjuvant approaches and the value of radiotherapy in the management of localised gastro-esophageal cancers
- To learn about the management of patients after progression, in special situations, and side effects of treatments
- To learn about the advances in the treatment and novel targets in gastric cancer

ACCREDITATION

The programme of this event has been accredited with **9 ESMO-MORA category 1 points**.

Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update her/his knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further details, please refer to [esmo.org](https://www.esmo.org).

ACKNOWLEDGEMENTS

This event is supported by an independent educational grant from

ORGANISATION AND CONTACTS

ESMO Head Office
Education Department
Via Ginevra 4, 6900 Lugano, Switzerland
Email: courses@esmo.org
www.esmo.org



Wednesday, 3 December 2025

09:30-09:40 10'	Welcome and introduction	Florian Lordick, DE Wei Peng Yong, SG
09:40-11:10 90'	SESSION 1 Epidemiology, pathology and staging of gastric cancer	Chair: Wei Peng Yong, SG Jimmy So, SG
25'	Epidemiology and pathogenesis	Florian Lordick, DE
25'	Pathology of gastric and state-of-the-art biomarkers	Jeffrey Lum, SG
25'	Diagnostic approach and treatment planning	Matthew C. H. Ng, SG
15'	Discussion	Faculty
11:10-11:40	Coffee break	
11:40-12:45 65'	SESSION 2 Treatment of early and localised gastric cancer	Chair: Florian Lordick, DE Maria Wobith, SG
25'	Endoscopic diagnosis and treatment	Takuji Gotoda, JP
25'	Surgical approach	Jimmy B. Y. So, SG
15'	Discussion	Faculty
12:45-13:45	Lunch	
13:45-15:15 90'	SESSION 3 Perioperative strategy of localised gastric cancer	Chair: Jimmy So, SG Radka Obermannová, CZ
25'	Adjuvant and perioperative chemotherapy of gastric cancer	Sun Young Rha, KR
25'	Integration of immune-therapy and targeted therapy	Wei Peng Yong, SG
25'	Perioperative management: Nutrition, early mobilization, prehabilitation	Maria Wobith, SG
15'	Discussion	Faculty
15:15-15:45	Coffee break	
15:45-16:45 60'	SESSION 4 Specific situation of metastatic gastric cancer	Chair: Sun Young Rha, KR Takuji Gotoda, JP
25'	Approaches to treatment of oligometastatic disease (liver, lung)	Hanneke van Laarhoven, NL
25'	Management of peritoneal metastases	Jimmy B. Y. So, SG
10'	Discussion	Faculty
16:45-17:15 30'	SESSION 5 Participants clinical case discussion	Chair: Florian Lordick, DE Wei Peng Yong, SG
30'	Participants clinical case discussion (2x15') (<i>locally advanced disease</i>)	Faculty
19:00	Networking dinner	

Thursday, 4 December 2025

09:00-10:30 90'	SESSION 6 Systemic treatment of metastatic gastric cancer	Chair: Matthew Ng, SG Hanneke van Laarhoven, NL
20'	Standard chemotherapy and sequencing	Florian Lordick, DE
20'	Immunotherapy	Sun Young Rha, KR
20'	Targeted therapy	Wei Peng Yong, SG
15'	Novel approaches to personalized oncology	Radka Obermannová, CZ
15'	Discussion	Faculty
10:30-11:00	Coffee break	
11:00-12:15 75'	SESSION 7 Participants clinical case discussion	Chair: Florian Lordick, DE Wei Peng Yong, SG
75'	Participants clinical case discussion (5x15') (<i>advanced disease</i>)	Faculty
12:15-12:20 5'	Conclusion and farewell	Florian Lordick, DE Wei Peng Yong, SG
12:20-13:20	Lunch	

Note: Each 15-minute slot for clinical case discussion includes a 7' case presentation and an 8' Q&A / panel discussion